Cargando…

Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs

BACKGROUND: Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies c...

Descripción completa

Detalles Bibliográficos
Autores principales: Menditto, Enrica, Orlando, Valentina, Coretti, Silvia, Putignano, Daria, Fiorentino, Denise, Ruggeri, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646475/
https://www.ncbi.nlm.nih.gov/pubmed/26635482
http://dx.doi.org/10.2147/CEOR.S88531
_version_ 1782400941999259648
author Menditto, Enrica
Orlando, Valentina
Coretti, Silvia
Putignano, Daria
Fiorentino, Denise
Ruggeri, Matteo
author_facet Menditto, Enrica
Orlando, Valentina
Coretti, Silvia
Putignano, Daria
Fiorentino, Denise
Ruggeri, Matteo
author_sort Menditto, Enrica
collection PubMed
description BACKGROUND: Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies cannot overlook their active role in determining health care resource allocation. This paper addresses this issue, investigating the effects of cost containment measures in the market of biosimilar drugs that represent a viable and cost-saving strategy for the reduction of health care expenditure. The analysis focuses on a particular region in Italy, where several timely policies to incentivize biosimilar prescribing were launched. METHODS: Drugs were identified by the anatomical therapeutic chemical classification system. Information about biosimilar drugs and their originator biological products was extracted from the IMS Health regional database. Drug consumption was expressed in terms of counting units, while expenditure was evaluated in Euro (€). The market penetration of biosimilars was analyzed by year and quarterly. RESULTS: In the Campania region of Italy, the effects of cost containment policies, launched between 2009 and 2013, showed the prescription of biosimilars strongly increasing in 2010 until prescribing levels reached and exceeded the market share of the reference biological products in 2012. After a slight reduction, a plateau was observed at the beginning of 2013. At the same time, the use of the originator products had been decreasing until the first quarter of 2011. However, after a 1-year plateau, this trend was reversed, with a new increase in the consumption of the originators observed. CONCLUSION: Results show that the cost containment policies, applied to cut health expenditure “to cure and not to care”, did not produce the cultural change necessary to make these policies effective in the long run. Therefore, top-down policies for cost containment are not successful; rather, a bottom-up approach based on consensus among professionals should become the preferred option.
format Online
Article
Text
id pubmed-4646475
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46464752015-12-03 Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs Menditto, Enrica Orlando, Valentina Coretti, Silvia Putignano, Daria Fiorentino, Denise Ruggeri, Matteo Clinicoecon Outcomes Res Original Research BACKGROUND: Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies cannot overlook their active role in determining health care resource allocation. This paper addresses this issue, investigating the effects of cost containment measures in the market of biosimilar drugs that represent a viable and cost-saving strategy for the reduction of health care expenditure. The analysis focuses on a particular region in Italy, where several timely policies to incentivize biosimilar prescribing were launched. METHODS: Drugs were identified by the anatomical therapeutic chemical classification system. Information about biosimilar drugs and their originator biological products was extracted from the IMS Health regional database. Drug consumption was expressed in terms of counting units, while expenditure was evaluated in Euro (€). The market penetration of biosimilars was analyzed by year and quarterly. RESULTS: In the Campania region of Italy, the effects of cost containment policies, launched between 2009 and 2013, showed the prescription of biosimilars strongly increasing in 2010 until prescribing levels reached and exceeded the market share of the reference biological products in 2012. After a slight reduction, a plateau was observed at the beginning of 2013. At the same time, the use of the originator products had been decreasing until the first quarter of 2011. However, after a 1-year plateau, this trend was reversed, with a new increase in the consumption of the originators observed. CONCLUSION: Results show that the cost containment policies, applied to cut health expenditure “to cure and not to care”, did not produce the cultural change necessary to make these policies effective in the long run. Therefore, top-down policies for cost containment are not successful; rather, a bottom-up approach based on consensus among professionals should become the preferred option. Dove Medical Press 2015-11-11 /pmc/articles/PMC4646475/ /pubmed/26635482 http://dx.doi.org/10.2147/CEOR.S88531 Text en © 2015 Menditto et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Menditto, Enrica
Orlando, Valentina
Coretti, Silvia
Putignano, Daria
Fiorentino, Denise
Ruggeri, Matteo
Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
title Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
title_full Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
title_fullStr Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
title_full_unstemmed Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
title_short Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
title_sort doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646475/
https://www.ncbi.nlm.nih.gov/pubmed/26635482
http://dx.doi.org/10.2147/CEOR.S88531
work_keys_str_mv AT mendittoenrica doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs
AT orlandovalentina doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs
AT corettisilvia doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs
AT putignanodaria doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs
AT fiorentinodenise doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs
AT ruggerimatteo doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs